Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Tripadvisor Inc Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.09 (market cap $2.86B), while Tripadvisor Inc Common Stock trades at $8.93 (market cap $1.02B). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 2.8× Tripadvisor Inc Common Stock's market cap, and Dyne Therapeutics Inc. Common Stock is more actively traded (3,341,579 versus 1,973,736). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Tripadvisor Inc Common Stock for 58 Days on average.
| DYN | TRIP | |
|---|---|---|
Market Cap | $2.86B | $1.02B |
Volume | 3,341,579 | 1,973,736 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $16.72 |
52-Week Low | $14.60 | $8.04 |
Typical Hold Time | 0 Days | 58 Days |
Enterprise Value | $2.18B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
TripAdvisor (TRIP) trades at $8.93, up 2.41% today but near its 52-week low of $8.27. The stock shows neutral technical signals with bearish moving averages. Fundamentally, revenue grew to $1.89B in 2025 with a net income margin of 2.11%, though recent quarters show earnings misses. The P/E ratio of 218.5 reflects high valuation relative to earnings, while P/S of 0.57 suggests reasonable sales valuation. Analyst sentiment is mixed with 62.5% hold ratings.
The outlook remains cautious due to competitive pressures from AI travel tools and uneven demand. Upside exists if Viator performance improves and TheFork sale completes, but risks include persistent earnings volatility and market share erosion. The consensus price target of $13.58 offers 52% potential upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
